PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Tofacitinib in Adult Patients With Moderate to Severe Ulcerative Colitis
- First Posted Date
- 2020-06-09
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 280
- Registration Number
- NCT04424303
- Locations
- 🇫🇷
Clinique de l Europe, Amiens, France
🇫🇷Hopital Sud, Amiens, France
🇫🇷Hopital Jean Minjoz, Besancon, France
TO ASSESS THE EFFICACY AND SAFETY OF PF-06650833, PF-06651600, AND TOFACITINIB ALONE AND IN COMBINATION IN PARTICIPANTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2020-06-04
- Last Posted Date
- 2023-04-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 460
- Registration Number
- NCT04413617
- Locations
- 🇧🇬
,,UMHAT - Georgi Stranski" EAD, Pleven, Bulgaria
🇧🇬Medical Diagnostic Laboratory Rusev EOOD, Plovdiv, Bulgaria
🇧🇬MHAT Plovdiv AD, Plovdiv, Bulgaria
Safety and Efficacy of Tofacitinib in Hospitalized Participants With COVID-19 Pneumonia Who Are Receiving Standard of Care Therapy
- First Posted Date
- 2020-06-02
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- Pfizer
- Registration Number
- NCT04412252
- Locations
- 🇺🇸
Hartford Hospital (HH), Hartford, Connecticut, United States
🇺🇸University of Iowa Hospitals & Clinics Investigational Drug Services, Iowa City, Iowa, United States
🇺🇸University of Iowa, Iowa City, Iowa, United States
Study Of Safety, Tolerability And Pharmacokinetics Of Subcutaneous Doses Of TA-46
- Conditions
- Healthy
- Interventions
- Biological: TA-46Other: Placebo
- First Posted Date
- 2020-06-01
- Last Posted Date
- 2020-06-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 78
- Registration Number
- NCT04410809
- Locations
- 🇳🇱
PRA, Groningen, Netherlands
Long-term Safety Study of BHV-3500 (Zavegepant*) for the Acute Treatment of Migraine
- First Posted Date
- 2020-05-29
- Last Posted Date
- 2023-05-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 974
- Registration Number
- NCT04408794
- Locations
- 🇺🇸
Medical Affiliated Research Center, Huntsville, Alabama, United States
🇺🇸Coastal Clinical Research, LLC, An AMR Co., Mobile, Alabama, United States
🇺🇸Tucson Neuroscience Research, Tucson, Arizona, United States
PK and Bioavailability Comparison of Tofacitinib Between a Modified Release and The Immediate Release Formulation
- First Posted Date
- 2020-05-27
- Last Posted Date
- 2020-05-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 26
- Registration Number
- NCT04403776
- Locations
- 🇨🇳
Shuguang Hospital Affiliated to Shanghai University of TCM/Phase I Unit, Shanghai, China
Study of Pharmacodynamics and Safety of DGAT2i and ACCi Coadministered in Participants With Sponsor-defined Presumed Non Alcoholic Steatohepatitis
- Conditions
- Nonalcoholic SteatohepatitisNonalcoholic Fatty Liver Disease
- Interventions
- First Posted Date
- 2020-05-22
- Last Posted Date
- 2023-04-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 75
- Registration Number
- NCT04399538
- Locations
- 🇺🇸
Clinical Trials Research, Lincoln, California, United States
🇺🇸Catalina Research Institute, LLC, Montclair, California, United States
🇺🇸Excel Medical Clinical Trials, Boca Raton, Florida, United States
Actigraphy Improvement With Voxelotor (ActIVe) Study
- First Posted Date
- 2020-05-22
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 25
- Registration Number
- NCT04400487
- Locations
- 🇺🇸
UConn Health, Farmington, Connecticut, United States
🇺🇸Children's Healthcare of Atlanta, Atlanta, Georgia, United States
🇺🇸Children's Hospital of Michigan, Detroit, Michigan, United States
Study to Evaluate the Efficacy of Enbrel as a Biological Treatment in Moderate to Severe Plaque Psoriasis Patients
- First Posted Date
- 2020-05-21
- Last Posted Date
- 2021-11-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 486
- Registration Number
- NCT04398732
- Locations
- 🇮🇶
Pfizer, Baghdad, Iraq
Moroctocog Alfa (AF-CC) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Hemophilia A Patients
- Conditions
- Hemophilia A
- Interventions
- Biological: Moroctocog-alfa (AF-CC)
- First Posted Date
- 2020-05-20
- Last Posted Date
- 2021-05-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 50
- Registration Number
- NCT04396639
- Locations
- 🇮🇳
Nirmal Hospital, Surat, Gujarat, India
🇮🇳K.J.Somaiya Hospital and Research Centre, Mumbai, Maharashtra, India
🇮🇳Sahyadri Clinical Research and Development Centre, Pune, Maharashtra, India